News
The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...
Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
MedPage Today on MSN7d
Semaglutide Gets FDA Greenlight for MASH
The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis ...
The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...
Everyday Health on MSN5d
People With Weight-Related Chronic Liver Disease Have a New Treatment Option
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...
Pharmaceutical Technology on MSN7d
Wegovy becomes first GLP-1RA to gain FDA MASH approval
Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback